4 Direct Oral Anticoagulants
Learn how direct oral anticoagulants are selected, dosed, monitored, and managed when interactions or serious bleeding occur.
Drug groups and uses
(DOACs) include the apixaban, rivaroxaban, and edoxaban, and the dabigatran. Depending on the drug and patient, they may be used to reduce stroke risk in nonvalvular atrial fibrillation, treat or prevent recurrence of (DVT) and (PE), or prevent some postoperative venous clots.
These medicines are not interchangeable. The indication, dose, food instructions, and renal restrictions differ by drug, so selection and use depend on the specific medicine and patient.
Indications and apixaban dose reduction
For nonvalvular atrial fibrillation, apixaban, rivaroxaban, edoxaban, or dabigatran may be considered to reduce stroke risk in eligible patients. A DOAC is not appropriate for every patient or indication; for example, mechanical heart valves require a different anticoagulation approach.
For apixaban in nonvalvular atrial fibrillation, the labeled reduced dose applies when at least two of these three criteria are present: age years, body weight kg, and serum creatinine mg/dL. Do not reduce the dose solely because the patient is older or has only one criterion; use the applicable product labeling and clinical assessment.
Food and administration
Rivaroxaban doses used for atrial fibrillation are taken once daily with the evening meal. Dabigatran capsules must be swallowed whole; they should not be opened or chewed because doing so can increase drug exposure. Food requirements differ among drugs and doses, so do not assume that every DOAC has the same food instructions.
Starting treatment for DVT or PE
For acute DVT or PE, apixaban and rivaroxaban have initial oral treatment regimens. Dabigatran and edoxaban treatment regimens generally begin after an initial course of parenteral anticoagulation. Follow the product labeling for the specific drug, indication, and regimen; there is no single initiation procedure that applies to every DOAC.
Interactions and bleeding risk
(P-gp) and interactions can change DOAC concentrations. Inhibitors may increase drug exposure and bleeding risk, while inducers may reduce exposure and compromise anticoagulation. The interaction and any needed action depend on the particular drug pair, indication, and kidney function; review these factors rather than assuming the combination is harmless or automatically changing the dose.
Aspirin, other antiplatelet agents, and nonsteroidal anti-inflammatory drugs (NSAIDs) can also increase bleeding risk.
Monitoring during treatment
Routine testing is not used to titrate DOAC doses. Standard clotting tests, including PT/ and aPTT, do not reliably quantify the anticoagulant effect across DOACs. Specialized assays calibrated for a particular drug may be considered in selected urgent situations.
Follow-up remains important. Periodically review adherence, bleeding or clotting symptoms, medications, complete blood count (CBC), kidney function, and liver function. Assess more often when clinical status or renal function warrants.
Reversal and major bleeding
is the specific reversal agent for dabigatran when bleeding is life-threatening or uncontrolled, and when urgent surgery or a procedure requires reversal.
In the United States, andexanet alfa was previously approved for apixaban- or rivaroxaban-associated life-threatening or uncontrolled bleeding. The manufacturer ended U.S. commercial sales in December 2025, and the FDA later listed the product as discontinued; it was no longer commercially available in the United States as of 2026.
For major bleeding, management includes stopping the DOAC and urgent supportive care and measures to control the bleeding source. Four-factor prothrombin complex concentrate () may be considered under local emergency protocols for factor Xa inhibitor-associated bleeding. Reversal decisions must balance bleeding control against thrombotic risk.